Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00510874 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 780
- Enrollment target
NCT00510874 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 780 participants.
The verdict
NCT00510874, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 780 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immune response of two-doses of GSK Biologicals' candidate influenza vaccine GSK 1557484A with or without adjuvant in adults. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Interventions
- BIOLOGICAL Pumarix™
- BIOLOGICAL Pandemrix ™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 780 participants |
| Start Date | 2007-07-28 |
| Est. Completion | 2008-10-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00510874
The ClinicalTrials.gov registry entry for NCT00510874 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 780 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pumarix™ is the first listed.
NCT00510874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00510874 about?
NCT00510874 is a clinical study titled "Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults". The purpose of this study is to evaluate the safety and immune response of two-doses of GSK Biologicals' candidate influenza vaccine GSK 1557484A with or without adjuvant in adults. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
What is the current status of trial NCT00510874?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 780 participants. The study started on 2007-07-28. Estimated completion is 2008-10-24.
What interventions are being tested in trial NCT00510874?
The interventions under investigation include: Pumarix™ (BIOLOGICAL), Pandemrix ™ (BIOLOGICAL).
Who is sponsoring clinical trial NCT00510874?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.